LEADER 02779nam  22006855  450 
001 9910298324703321
005 20251105120425.0
010   $a3-319-00978-8
024 7 $a10.1007/978-3-319-00978-0
035   $a(CKB)2550000001166534
035   $a(EBL)1592324
035   $a(OCoLC)897576910
035   $a(SSID)ssj0001066480
035   $a(PQKBManifestationID)11585485
035   $a(PQKBTitleCode)TC0001066480
035   $a(PQKBWorkID)11067048
035   $a(PQKB)10347637
035   $a(MiAaPQ)EBC1592324
035   $a(DE-He213)978-3-319-00978-0
035   $a(PPN)176103503
035   $a(EXLCZ)992550000001166534
100   $a20131107d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aMolecular Vaccines $eFrom Prophylaxis to Therapy - Volume 2 /$fedited by Matthias Giese
205   $a1st ed. 2014.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2014.
215   $a1 online resource (434 p.)
300   $aDescription based upon print version of record.
311 08$a3-319-00977-X 
311 08$a1-306-16576-8 
320   $aIncludes bibliographical references and index.
327   $aNon-infectious and non-cancer vaccines -- Adjuvants and nanotechnology -- In silico and delivery systems -- Patenting, manufacturing, registration.
330   $aThis title discusses all aspects of non-infectious and non-cancer? so called NINC ? vaccines. Hypertension, diabetes and allergy vaccine development are referred to as well as the use of adjuvants and nanotechnology in vaccine development. The way of novel vaccines from bench to preclinical to clinical studies and launch to the market under EMEA (European Medicines Agency) and FDA (Food and Drug Administration) guidelines are described in-depth. Practical perspectives of patentability of vaccines are discussed. The book is therefore of interest for researchers and clinicians engaged in vaccine development and molecular vaccine application.
606   $aPharmacology
606   $aImmunology
606   $aMedicine$xResearch
606   $aBiology$xResearch
606   $aPharmacology
606   $aImmunology
606   $aBiomedical Research
615  0$aPharmacology.
615  0$aImmunology.
615  0$aMedicine$xResearch.
615  0$aBiology$xResearch.
615 14$aPharmacology.
615 24$aImmunology.
615 24$aBiomedical Research.
676   $a610
676   $a611.01816
676   $a615.372
676   $a615372
702   $aGiese$b Matthias$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298324703321
996   $aMolecular Vaccines$92537239
997   $aUNINA